PCM
EGRX

Penserra Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Penserra Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300
Closed -$16K – 1589
2021
Q3 		$16K Hold
300
– – ﹤0.01% 1289
2021
Q2 		$12K Buy
300
+10
+3% +$413 ﹤0.01% 1263
2021
Q1 		$12K Sell
290
-10
-3% -$464 ﹤0.01% 1016
2020
Q4 		$13K Buy
300
+182
+154% +$8.51K ﹤0.01% 904
2020
Q3 		$5K Buy
+118
New +$5.16K ﹤0.01% 861

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Penserra Capital Management's EGRX Position: Q4 2021 in Review

Penserra Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2021, closing a stake of 300 shares — an estimated $16K sold.

Penserra Capital Management first reported a position in EGRX in Q3 2020 and held it in 5 quarters. The position peaked at $16K in Q3 2021. 162 funds tracked by Wall St. Rank hold EGRX as of Q4 2021.

  • Penserra Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 300 Eagle Pharmaceuticals, Inc. shares in Q4 2021, an estimated $16K.
  • Penserra Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $16K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.